Work Here?
Overview
BreezeBio develops gene therapies and gene-editing solutions using a CRISPR delivery system built from engineered CRISPR components and a proprietary polymer nanoparticle library. It packages CRISPR components into polymer nanoparticles that deliver Cas9 and guide RNAs to target cells, enabling tissue-specific gene edits. The company differentiates itself by combining in-house polymer nanoparticle technology with component-level CRISPR engineering, supported by proof-of-concept data and industry partnerships. Its goal is to commercialize the delivery platform and resulting therapeutics through licensing, partnerships, and direct sales to medical and healthcare clients.
About BreezeBio
Industries
Biotechnology
Healthcare
Company Size
51-200
Company Stage
Series B
Total Funding
$118.5M
Headquarters
Brisbane, California
Founded
2016
People at BreezeBio
People at BreezeBio who can refer or advise you
Simplify's Take
What believers are saying
- BRZ-101 induced antigen-specific tolerance in NOD mice and tolerated mice and non-human primates preclinically
- $60M Series B funding advances IND-enabling studies and expands NanoGalaxy for in vivo CAR-T delivery
- Scientific Advisory Board includes experts from Capstan Therapeutics and Eli Lilly guiding pipeline development
What critics are saying
- BRZ-101 IND failure or negative non-human primate toxicology halts T1D pipeline and burns $60M cash in 6–12 months
- Capstan or Eli Lilly competitor launches superior non-viral immune tolerance mRNA therapy for T1D in 12–18 months
- NanoGalaxy fails to scale in vivo CAR-T due to off-target T-cell transfection, invalidating oncology strategy in 12–18 months
What makes BreezeBio unique
- BreezeBio transitioned from delivery platform to internal therapeutics developer for autoimmune diseases and oncology
- NanoGalaxy platform enables targeted, non-viral delivery to immune, cardiac, pulmonary, and central nervous systems
- BRZ-101 uniquely restores immune tolerance in type 1 diabetes via mRNA-encoded autoantigens and tolerogenic co-factors
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$118.5M
Above
Industry Average
Funded Over
4 Rounds
Industry standards
Growth & Insights and Company News
6 month growth
↑ 3%1 year growth
↑ 0%2 year growth
↑ 0%Gene therapy company Sarepta has announced a partnership with GenEdit, a startup that develops gene-editing technology.
BreezeBio is Hiring for 4 Jobs on Simplify!
Find jobs on Simplify and start your career today
About BreezeBio
Industries
Biotechnology
Healthcare
Company Size
51-200
Company Stage
Series B
Total Funding
$118.5M
Headquarters
Brisbane, California
Founded
2016
BreezeBio is Hiring for 4 Jobs on Simplify!
Find jobs on Simplify and start your career today